EDETOX logo

IN VIVO STUDIES FURTHER DETAILS

In Vivo Study No: 306

METHODS

Chemical	Membrane	Concentration mg/ml	Concentration mg/ml	loading (mg/cm2)	Species	Site	Area (cm2)	Occluded?	Exposure Time (h)	Analytical Method
Malathion	0.02	1200	5.2	None (Neat)	Human	Ventral Forearm	4.6	2	24	Radiolabelled (14C)

RESULTS

Length of Study (h)	% Recovery	+/-	Dose remaining on surface (mg)	% remaining on Surface	Dose remaining in stratum corneum (mg)	% remaining in stratum corneum	Dose remaining in the viable skin	% remaining in the viable skin	Amount Absorbed (mg)	% Absorbed	+/-	% Absorbed
									1.07	4.48	1.3	4.48

Length of Study (h)

% Recovery

+/-

Dose remaining on surface (mg)

% remaining on Surface

Dose remaining in stratum corneum (mg)

% remaining in stratum corneum

Dose remaining in the viable skin

% remaining in the viable skin

Amount Absorbed (mg)

% Absorbed

+/-

% Absorbed

1.07

4.48

1.3

4.48

Maximal Flux (mcrg/cm2/h)	Average Flux (mcrg/cm2/h)	+/-	Time Plasma/Blood Levels Peaked (h)	Peak Blood Concentration (mg/l)	n	kp (cm/h)	Lag Time (h)
					5

NOTES

Doses of 20 microlitres of cold Malathion were added every day until the end of the experiment. The excretion of these doses was not measured. The % absorbed dose has been derived from that present in the urine. Urine samples were collected at 4, 8 and 12 hours on the first day and every 24 hours thereafter. All calculated urinary excretion values were corrected for excretion by other route with a human parenteral urinary excretion factor (90.2%) from Feldmann and Maibach (1974) Toxicol.appl. Pharmacol. 28 126-132

REFERENCE

Malathion Percutaneous Absorption After Repeated Administration To Man (1983) Toxicol. Appl. Pharmacol., 68 :116-119